TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05254093

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: quadratus lumborum block, anterior approach using a curvilinear (5-8MHz) transducer. The transducer will be positioned transverse above the iliac crest at the posterior axillary line and slided posteriorly till the Shamrock sign is identified (the transvers process represent the stem and the attached erector spinae, QL and Psoas major muscles represent the three leaves). A 22 G, 100 mm needle will be advanced in-plane from lateral to medial through the QL muscle to reach the inter-fascial plane between the QL and psoas major muscles, posterior to the transversalis fascia. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected anterior to the QL muscle. The procedure will be repeated on the opposite side of the back

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: the block will be given at the level of the 9th thoracic transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T9) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected below the muscle. The procedure will be repeated on the opposite side of the back
Study: NCT06516302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR1802
Description: GR1802 will be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered SC.
Study: NCT04917029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride perineurally
Description: Arm 1; Bupivacaine hydrochloride 40 ml 0.25% perineurally in FICB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride perineurally
Description: Arm 1; Bupivacaine hydrochloride 40 ml 0.25% perineurally in FICB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetmidine infusion
Description: Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine perineurally
Description: Arm 2:Dexmedetomidine perineurally in FICB 80µg
Study: NCT06523465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin combined with Amlodipine besylate
Description: 6-month treatment of Simvastatin combined with Amlodipine besylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin combined with Spironolactone and Amlodipine besylate.
Description: 6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate combined Spironolactone
Description: 6-month treatment of Amlodipine besylate combined with Spironolactone
Study: NCT05163431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hallux Valgus orthosis
Description: Custom designed orthosis and manufactured by 3D printing.
Study: NCT06213441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pecha kucha education
Description: Pecha kucha training to be given to the experimental arm will be given by the researcher.~The training content will be created in line with the literature and will be given before the patient is discharged.
Study: NCT06438354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: subgingival instrumentation plus Perisolv / hyaDent BG
Description: Group A: Perisolv is applied prior to subgingival instrumentation for disinfecting purpose, hyaDent BG seals the site for accelerated blood clot stabilisation and support of cell proliferation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: subgingival instrumentation
Description: Group B: sites requiring re-treatment are subjected to subgingival scaling
Study: NCT05755724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-D Teaching
Description: Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2-D Teaching
Description: Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
Study: NCT06401603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listaftoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listaftoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Given by PO
Study: NCT06283745

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich Plasma (PRP)
Description: Platelet-rich plasma (PRP) intranasal injection in the treatment of qualitative olfactory dysfunction (parosmia). This is taken from a blog draw from the patient themselves, and thus no external drug/biologic product will be given - only the concentrated plasma portion from the patient's own blood.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline intranasal injection (sham injection)
Study: NCT05612178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10- 1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
Study: NCT05804214

Intervention type: OTHER
Intervention: Dairy and plant based infant formula feeding
Description: Parents have already decided to feed their infant with the product (a dairy and plant based infant formula) daily, starting within the first 4 months of life, continuing for at least 2 months
Study: NCT04909853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: PF-07321332 in combination with the PK boosting agent, ritonavir, being developed for the treatment of COVID-19
Study: NCT05531812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G2R with individual coaching
Description: 1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Individual coaching at home from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; Water, Sanitation and Hygiene (WASH) practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G2R with group coaching
Description: 1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Group coaching in a community setting from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; WASH practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services.
Study: NCT06578793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation Combined with Marshall Vein Ethanol Ablation
Description: This study involves two procedures. The first procedure is a combination of catheter ablation with ethanol ablation of the Marshall vein. The second procedure is catheter ablation alone. Both procedures involve standard techniques used to treat persistent atrial fibrillation, with the addition of Marshall vein ethanol ablation in the experimental group aimed at potentially improving outcomes by targeting additional arrhythmogenic substrates.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation Combined with Marshall Vein Ethanol Ablation
Description: This study involves two procedures. The first procedure is a combination of catheter ablation with ethanol ablation of the Marshall vein. The second procedure is catheter ablation alone. Both procedures involve standard techniques used to treat persistent atrial fibrillation, with the addition of Marshall vein ethanol ablation in the experimental group aimed at potentially improving outcomes by targeting additional arrhythmogenic substrates.
Study: NCT05889936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lev
Description: Lev includes three sessions using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev also include two homework assignments. The second session can be repeated if needed. Lev-s and Lev are described in two manuals.
Study: NCT05581693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04RD1
Description: 1 tablet of L04RD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04TD2
Description: 1 tablet of L04TD2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04TD2
Description: 1 tablet of L04TD2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04RD1
Description: 1 tablet of L04RD1
Study: NCT06206005

Intervention type: OTHER
Intervention: Observational study
Description: evaluate implant survival, peri-implant outcome of 4 implant retained mandibular OVD after 10 years of function.

Intervention type: OTHER
Intervention: Observational study
Description: evaluate implant survival, peri-implant outcome of 4 implant retained mandibular OVD after 10 years of function.
Study: NCT05612178

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks, 20 and 40.
Study: NCT06254963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sand jump training
Description: A series of progressive jumping activities on sand increasing in difficulty over the 6 week period
Study: NCT03990467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma dosage of amikacin, piperacillin and tazobactam
Description: Pharmacokinetic (PK) criteria will be used to judge whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam
Study: NCT05801705

Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor includes Arimidex, Aromasin, Femara.

Intervention type: PROCEDURE
Intervention: ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)
Description: Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin

Intervention type: PROCEDURE
Intervention: ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)
Description: Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin

Intervention type: PROCEDURE
Intervention: ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)
Description: Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin

Intervention type: DRUG
Intervention: Tamoxifen
Description: tamoxifen,10mg, bid

Intervention type: DRUG
Intervention: toremifene
Description: toremifene, 60 mg, qd
Study: NCT06250296

Intervention type: OTHER
Intervention: New model of psychiatric inpatient care
Description: The intervention envisages major structural changes in wards, in particular the reorganization of clinical discussion and decision-making spaces, as well as the medical and nursing referral system, and the inclusion of relatives in care:~* Treatment planning involving the patient, with a focus on his or her needs and resources.~* Care by referral teams, present every day of the week, to ensure continuity and consistency of care.~* As few decisions as possible made without the patient, and transparency in decision-making.~* Emphasis on the subjective meaning of illness, beyond symptoms.~* Greater visibility of care planning for patients, who will benefit from weekly agendas~* Closer collaboration with relatives, through open invitations to all clinical discussions, telephone hotlines and meeting times.~* Openness to the network and community care, by promoting communication and exchanges between all stakeholders, and the development of early warning tools such as the joint crisis plan.
Study: NCT06055361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BxC-I17e
Description: Pharmaceutical form : solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BxC-I17e
Description: Pharmaceutical form : solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form : solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form : solution for injection
Study: NCT04712344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Description: Infusion of a total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 in Addition to standard treatment.
Study: NCT05790395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention
Description: The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: health-risk behaviors
Description: The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
Study: NCT05208190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: treatment will occur naturalistically, as per standard clinical guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: naturalistic treatment with any other antipsychotic medication except clozapine
Study: NCT06431724

Intervention type: OTHER
Intervention: Patient Survey
Description: A simple data intake collection from the patients regarding their medical history that will allow the researchers to assess if recommended guidelines were followed.
Study: NCT05095584

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3 meter backward walk test
Description: validity and reliability of 3-meter backward walk test in lower limb amputation group
Study: NCT05036122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabClasp
Description: Non-invasive device that estimates blood \[lactate\] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood \[lactate\] and return a value to the subject via an accompanying tablet within 20 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabClasp
Description: Non-invasive device that estimates blood \[lactate\] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood \[lactate\] and return a value to the subject via an accompanying tablet within 20 seconds.
Study: NCT06254963

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: land jump training
Description: A series of progressive jumping activities on land increasing in difficulty over the 6 week period
Study: NCT05658107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765423
Description: BI 765423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04933903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg IV on day 1 (1 dose total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 1 fraction or 2 fractions delivered to the gross primary tumor and nodal disease, following the first treatment with ipilimumab + nivolumab on days 1-3.
Study: NCT05867173

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Experimental Speech Processing Strategy
Description: Patient's will listen with an experimental speech processor, programmed with a dynamic focusing strategy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Speech Processing Strategy
Description: Patient's will listen with an experimental speech processor, programmed with a dynamic focusing strategy.
Study: NCT06216301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T
Description: The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death.~Drug: Pembrolizumab. Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.~Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Study: NCT06431724

Intervention type: OTHER
Intervention: Provider Survey
Description: A survey will be used to evaluate providers' practices, knowledge and adherence to guidelines, and decision making related to current practice for cervical screening in women \>65.
Study: NCT06216301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Study: NCT06405984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal Oxygenation Measurements
Description: The Lumerah device, and Oxiplex ISS will be positioned on the maternal abdomen in various locations depending on the sonographic evaluation. The transvaginal sensor will be placed after rupture of the maternal membranes and appropriate descent of the fetus.This study is for data collection purposes only. Neonates of this study arm will also be monitored with the Oxiplex ISS system. This study is for data collection purposes only.
Study: NCT06216301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum based chemotherapy
Description: Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer
Study: NCT06639854

Intervention type: OTHER
Intervention: Hematopoietic Cell Transplant
Description: Participants choices may include to receive standard post-transplant virus prevention with letermovir or other standard drugs without being part of this study. Participants may choose to receive other investigational therapy, if available.~These alternative treatments have risks and benefits that may be the same or different than those in this research study.
Study: NCT04711512

Intervention type: BEHAVIORAL
Intervention: Encouragement/Support
Description: Messages that focus on improving self-efficacy and motivation for physical activity

Intervention type: BEHAVIORAL
Intervention: Social Comparison
Description: Messages that provide exposure to another person's physical activity engagement data (for comparison)
Study: NCT05758025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection based on thymus-vascular-inferior parathyroid complex
Description: Before clearing the central lymph nodes, looking for the thyro-thymic ligament first, looking for the inferior parathyroid along the thyro-thymic ligament. Dissect and leave the thymus-vascular-inferior parathyroid complex laterally; the inner side of this layer is the tissue of the central area. Then remove the central lymph nodes. Check for parathyroids in the removed specimen, transplant the parathyroids which are removed by accident.
Study: NCT05705544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILLUMISITE™ Platform (EMN bronchoscopy)
Description: Providers will utilize the ILLUMISITE™ Platform (EMN) machine to perform a diagnostic bronchoscopy procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ion™ Endoluminal System (SSCB bronchoscopy)
Description: Providers will utilize the Ion™ Endoluminal System (SSCB) machine to perform a diagnostic bronchoscopy procedure.
Study: NCT05768711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Combination of Azacitidine and Venetoclax